A new bill introduced in the Maryland House of Delegates requests that pharmas be more specific about the brands related to ...

The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring.  | The company is working with regulators to ensure stable ongoing supply for the one-time gene therapy ...

Alfasigma’s buzzer-beater bet on GSK’s rare liver disease prospect has paid off. | Lynavoy is now the first FDA-approved product that can treat cholestatic pruritus in patients with primary biliary ...

Following through with its sizable investment commitment in China, AstraZeneca on Thursday unveiled plans to build a commercial cell therapy manufacturing base and an innovation center dedicated to | ...

Still basking in the afterglow of its Wegovy pill launch earlier this year, Novo has achieved another victory as it strives to make the most out of its blockbuster GLP-1 drug in an increasingly ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...

Axplora, a German CDMO that specializes in specialty active pharmaceutical ingredients for small molecules and antibody-drug conjugates, will ...

Bristol Myers Squibb has added a familiar face to an ongoing initiative to thank oncologists for the valuable time they ...

Sandoz has struck a deal with Samsung Bioepis to partner on up to five biosimilars, with the first being SB36, a copycat of ...

Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the lucrative psoriasis market with a new approval for a much-anticipate | The ...

Some three weeks into the U.S. and Israel’s war with Iran, the expanding conflict’s impact on energy prices and shipping in ...

Everyone’s favorite bracket challenge has returned. That’s right—it’s time once again for Fierce Pharma Marketing’s annual ...